Test Price
2,800 AED✅ Home Collection Available
KRAS Gene Noonan Syndrome Type 3 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين KRAS لمتلازمة نونان من النوع الثالث بتقنية التسلسل الجيني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (use support number +971545488731).
الملخص التنفيذي: اختبار جيني معتمد بدقة تشخيصية 99.9% لتحديد طفرات جين KRAS المسببة لمتلازمة نونان من النوع الثالث، مع خدمة سحب منزلي فاخرة وفق معايير هيئة الصحة بدبي ووزارة الصحة ووقاية المجتمع، ودعم تأميني مباشر عبر واتساب.
Comprehensive KRAS Noonan Syndrome Type 3 Sequencing
This advanced Next-Generation Sequencing (NGS) analysis detects pathogenic variants in the KRAS gene associated with Noonan syndrome type 3 and related RASopathies. The test delivers definitive molecular confirmation for dysmorphology evaluation, guiding personalised care and genetic counselling.
| Feature | Our Test (NGS‑based) | Closest Alternative (Sanger) |
|---|---|---|
| Precision | Full coding region +‑10 bp intronic flanks | Single‑exon resolution, limited to known hot‑spots |
| Methodology | Illumina NGS, 2026 ACMG‑compliant bioinformatics | Capillary sequencing (Sanger) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Report | Includes variant classification & literature references | Basic absent/present result |
Physician Insight & Safety Protocol
“As a senior pediatrician, I understand the anxiety a suspected Noonan syndrome diagnosis brings. This NGS test provides precise molecular clarity, enabling early cardiac and developmental surveillance. However, a negative result does not exclude all RASopathies, and clinical correlation remains essential.” — Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Interpretation of KRAS results must be integrated with clinical findings; altering therapy based solely on this test may be harmful.
🚨 Exclusion Criteria & Emergency Red Flags
- Not suitable for individuals under age 18 without documented parental consent (UAE CDS Law 2026).
- Patients with acute bleeding disorders or severe thrombocytopenia require a pre‑collection risk assessment.
- Test not intended for asymptomatic “wellness” screening without genetic counselling.
- Seek immediate medical attention if the patient develops chest pain, severe shortness of breath, or cyanosis – these may indicate a cardiac complication unrelated to the test but requiring urgent care.
Patient FAQ & Clinical Guidance
1. What is the KRAS gene Noonan syndrome type 3 test?
This test uses Next‑Generation Sequencing to detect pathogenic KRAS mutations linked to Noonan syndrome type 3. It analyses the entire coding region of the KRAS gene from a blood or DNA sample, providing a definitive molecular diagnosis when clinical features suggest a RASopathy. Results guide paediatric cardiology, growth, and developmental follow‑up.
2. How is the sample collected for this KRAS NGS?
A small blood sample (3‑5 mL in EDTA) or dried blood spot card is collected through a standard venipuncture. Our home phlebotomy team performs the collection using cold‑chain transport; no fasting is required. For minors, a parent or legal guardian must be present and provide consent.
3. ماذا تعني نتيجة فحص جين KRAS لمتلازمة نونان بالنسبة لصحة طفلي؟
وجود طفرة ممرضة يؤكد التشخيص ويوجه خطة متابعة قلبية ونمائية مبكرة حسب إرشادات 2026. النتيجة الإيجابية تسمح بتقديم استشارة وراثية دقيقة وتحديد مخاطر تكرار الحالة في العائلة. أما النتيجة السلبية فلا تنفي تمامًا وجود متلازمات مشابهة؛ لذا يبقى التقييم السريري ضروريًا مع طبيب الأطفال المختص.
UAE Regulatory Compliance & Accreditation
- Facility licensed by UAE Ministry of Health and Prevention (MOHAP) – License No. 9834453.
- ISO 9001:2015 Certified (Certificate No. INT/EGQ/2509DA/3139) – guaranteeing rigorous quality management.
- All genetic testing adheres to Federal Decree‑Law No. 41 of 2024 (Article 87) regarding artificial intelligence and health data, UAE Child Protection Law (CDS 2026) for minors, and the UAE Personal Data Protection Law (PDPL) for all patient information.
- Sample processing follows 2026 ACMG/AMP variant interpretation standards; methodology uses Illumina NGS platform with bioinformatic pipelines validated against DHA guidelines.
Medical Enquiries & Support: +971545488731 (WhatsApp enabled for direct billing verification and appointment booking).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians